Intermediate Fibroblastic Neoplasm

subtype

Identifier: CI-CAN-00001015
Entity page: /cancer/intermediate-fibroblastic-neoplasm ↗
Edges: 156

Neighbours: 28 drugs10 trials
Drawn: 38 of 38 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Intermediate Fibroblastic Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived28 of 28show fewer
→ investigated in trials for	Nirogacestatsmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Intermediate Fibroblastic Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinib Mesylatesmall molecule

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ALK Fusion Crizotinib1 active / 3 trials
Curatedlevel Asensitivity· support 3civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Inflammatory Myofibroblastic Tumor
ROS1 Fusion EntrectinibEMA EU 2020-07-310 active / 0 trials
Curatedlevel Csensitivity· support 2civicObservedcohort frequency not yet available for ROS1 in this cancerRegulatoryapproved for Lung Non-Small Cell Carcinoma (3 approval records)context: Inflammatory Myofibroblastic Tumor
ALK Fusion Crizotinib1 active / 3 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ALK in this cancerno approval record in this cancercontext: Inflammatory Myofibroblastic Tumor
ALK Fusion EntrectinibEMA EU 2020-07-310 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ALK in this cancerRegulatoryapproved for Lung Non-Small Cell Carcinoma (3 approval records)context: Inflammatory Myofibroblastic Tumor
PDGFB Fusion Sunitinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for PDGFB in this cancerno approval record in this cancercontext: Dermatofibrosarcoma Protuberans
PDGFRB Overexpression Sunitinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for PDGFRB in this cancerno approval record in this cancercontext: Dermatofibrosarcoma Protuberans
ROS1 Fusion Crizotinib1 active / 3 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for ROS1 in this cancerno approval record in this cancercontext: Inflammatory Myofibroblastic Tumor
CDKN2A Loss Palbociclib0 active / 0 trials
Curatedlevel Dsensitivity· support 1civicObservedcohort frequency not yet available for CDKN2A in this cancerno approval record in this cancercontext: Dermatofibrosarcoma Protuberans

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Intermediate Fibroblastic Neoplasm studied in …STUDIED_INderived10 of 128show all (up to 200)
→ studied in	NCT07755176enrolling by invitation Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07158892NA · not yet recruiting Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Palmar Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07170644Phase 2 · active not recruiting A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT07176689Phase 4 · recruiting Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT05949099Phase 2 · recruiting Study of Cryoablation and Nirogacestat for Desmoid Tumor · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT02402244recruiting Project: Every Child for Younger Patients With Cancer · condition mapped ONTOLOGY_EXACT · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT04851119Phase 1/Phase 2 · recruiting Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors · condition mapped CURATED_BROADER · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT03785964Phase 3 · completed Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) · condition mapped ALIAS · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →
→ studied in	NCT06239272Phase 1/Phase 2 · recruiting NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) · condition mapped ONTOLOGY_EXACT · 128 trials mapped (38 active)	—	—	Fibrosarcomatous Dermatofibrosarcoma Protuberans	1	Observed	clinicaltrials	graph →
→ studied in	NCT04195399Phase 2 · active not recruiting A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 128 trials mapped (38 active)	—	—	Desmoid Fibromatosis	1	Observed	clinicaltrials	graph →